Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Privigen hemolysis mechanism in chronic ITP
NCT01390649Phase 4Completed
- Sponsor
- CSL Limited
- Start
- Nov 2011
- Primary completion
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of intravenous immunoglobulin G, sponsored by CSL Limited. Primary endpoint: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis at 3 days. Started Nov 2011; status: completed.
02
Drugs
intravenous immunoglobulin G
Beyond the preview
Go deeper on NCT01390649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01390649.